Compare AbbVie Inc (ABBV) vs ADT Inc (ADT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs ADT Inc — how do they compare? AbbVie Inc trades at $248.48 (market cap $441.94B), while ADT Inc trades at $7.45 (market cap $5.44B). The key difference: AbbVie Inc is far larger — about 81.2× ADT Inc's market cap, and ADT Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| ABBV | ADT | |
|---|---|---|
Market Cap | $441.94B | $5.44B |
Sector | Health | Industrials |
52-Week High | $263.58 | $8.85 |
52-Week Low | $197.38 | $6.30 |
Enterprise Value | $506.19B | $13.13B |
Dividend Yield | 2.77% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
ADT trades at $7.51, down 1.7% today, amid strong technical momentum with bullish moving averages and ADX signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.23 beating estimates of $0.22, and improving profitability with net margin reaching 11.86% in 2025. Recent news highlights ADT's Zacks upgrade to Buy and strong Q2 results with 18% operating cash flow growth.
ADT presents a compelling value opportunity with attractive valuation multiples (P/E 10.35, EV/EBITDA 4.93) and bullish analyst sentiment (47% Buy ratings). Key risks include high debt levels ($7.51B long-term debt) and competitive pressures in security services. The stock's technical strength and fundamental improvements support a positive near-term outlook, though investors should monitor debt management and industry competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →
